Matches in SemOpenAlex for { <https://semopenalex.org/work/W2419146865> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2419146865 endingPage "9" @default.
- W2419146865 startingPage "985" @default.
- W2419146865 abstract "To observe the efficacy and adverse reaction of the improvement program of cladribine combined with cytarabine (2-CdA+Ara-C) in treatment of children with refractory high-risk Langerhans cell histiocytosis (LCH).13 patients with refractory high-risk LCH or recurrent LCH were treated by combined 2-CdA+Ara-C chemotherapy. The treatment efficacy and the disease state in the process were evaluated according to the Histiocyte Society Evaluation and Treatment Guidelines (2009). The drug toxicity was evaluated according to the Common Terminology Criteria Adverse Events Version 4.0 (CTCAE v4.0, 2009).Of 13 patients, 10 cases achieved non active disease (NAD); 2 patients with liver cirrhosis before the improvement program with CIP-LCH-2012 gave up the treatment after 1 course of therapy; 1 patient died of infectious shock after chemotherapy with severe pulmonary infection and intestinal infection. All 13 patients had grade 3 of blood and lymphatic system toxicity; 10 patients had grade 1 of hepatobiliary and gastrointestinal side effects; 3 patients with liver cirrhosis before the improvement program had grade 2 or grade 3 of hepatobiliary system and gastrointestinal system side effects, including 1 patient of death.The improvement program of CIP-LCH-2012 had significant efficacy for children with refractory high-risk and relapsed LCH. The cladribine-associated toxicity was of significant myelosuppression, which may be tolerated in the most children patients. The program could be considered as a recommended salvage therapy for multi-system LCH (MS-LCH) after failure of first-line therapy, and as a first-line therapy for MS-LCH with risk organ injury. The program should be used with caution or dose-adjustment consideration for pre-treatment of severe organ damage exist, especially cirrhosis." @default.
- W2419146865 created "2016-06-24" @default.
- W2419146865 creator A5012178882 @default.
- W2419146865 creator A5038446303 @default.
- W2419146865 creator A5052883326 @default.
- W2419146865 creator A5061729366 @default.
- W2419146865 creator A5065297872 @default.
- W2419146865 creator A5075401128 @default.
- W2419146865 creator A5089837115 @default.
- W2419146865 creator A5090124257 @default.
- W2419146865 date "2014-11-01" @default.
- W2419146865 modified "2023-10-16" @default.
- W2419146865 title "[Cladribine for 13 cases refractory high-risk children Langerhans cell histiocytosis]." @default.
- W2419146865 doi "https://doi.org/10.3760/cma.j.issn.0253-2727.2014.11.007" @default.
- W2419146865 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25417874" @default.
- W2419146865 hasPublicationYear "2014" @default.
- W2419146865 type Work @default.
- W2419146865 sameAs 2419146865 @default.
- W2419146865 citedByCount "0" @default.
- W2419146865 crossrefType "journal-article" @default.
- W2419146865 hasAuthorship W2419146865A5012178882 @default.
- W2419146865 hasAuthorship W2419146865A5038446303 @default.
- W2419146865 hasAuthorship W2419146865A5052883326 @default.
- W2419146865 hasAuthorship W2419146865A5061729366 @default.
- W2419146865 hasAuthorship W2419146865A5065297872 @default.
- W2419146865 hasAuthorship W2419146865A5075401128 @default.
- W2419146865 hasAuthorship W2419146865A5089837115 @default.
- W2419146865 hasAuthorship W2419146865A5090124257 @default.
- W2419146865 hasConcept C121332964 @default.
- W2419146865 hasConcept C126322002 @default.
- W2419146865 hasConcept C141071460 @default.
- W2419146865 hasConcept C142424586 @default.
- W2419146865 hasConcept C197934379 @default.
- W2419146865 hasConcept C2776694085 @default.
- W2419146865 hasConcept C2777484599 @default.
- W2419146865 hasConcept C2777793932 @default.
- W2419146865 hasConcept C2779134260 @default.
- W2419146865 hasConcept C2779200787 @default.
- W2419146865 hasConcept C2780775027 @default.
- W2419146865 hasConcept C71924100 @default.
- W2419146865 hasConcept C87355193 @default.
- W2419146865 hasConcept C90924648 @default.
- W2419146865 hasConceptScore W2419146865C121332964 @default.
- W2419146865 hasConceptScore W2419146865C126322002 @default.
- W2419146865 hasConceptScore W2419146865C141071460 @default.
- W2419146865 hasConceptScore W2419146865C142424586 @default.
- W2419146865 hasConceptScore W2419146865C197934379 @default.
- W2419146865 hasConceptScore W2419146865C2776694085 @default.
- W2419146865 hasConceptScore W2419146865C2777484599 @default.
- W2419146865 hasConceptScore W2419146865C2777793932 @default.
- W2419146865 hasConceptScore W2419146865C2779134260 @default.
- W2419146865 hasConceptScore W2419146865C2779200787 @default.
- W2419146865 hasConceptScore W2419146865C2780775027 @default.
- W2419146865 hasConceptScore W2419146865C71924100 @default.
- W2419146865 hasConceptScore W2419146865C87355193 @default.
- W2419146865 hasConceptScore W2419146865C90924648 @default.
- W2419146865 hasIssue "11" @default.
- W2419146865 hasLocation W24191468651 @default.
- W2419146865 hasOpenAccess W2419146865 @default.
- W2419146865 hasPrimaryLocation W24191468651 @default.
- W2419146865 hasRelatedWork W2041235190 @default.
- W2419146865 hasRelatedWork W2168233212 @default.
- W2419146865 hasRelatedWork W2415576058 @default.
- W2419146865 hasRelatedWork W2419146865 @default.
- W2419146865 hasRelatedWork W2467023771 @default.
- W2419146865 hasRelatedWork W2768478926 @default.
- W2419146865 hasRelatedWork W2805180472 @default.
- W2419146865 hasRelatedWork W3031756279 @default.
- W2419146865 hasRelatedWork W3031860254 @default.
- W2419146865 hasRelatedWork W3196162770 @default.
- W2419146865 hasVolume "35" @default.
- W2419146865 isParatext "false" @default.
- W2419146865 isRetracted "false" @default.
- W2419146865 magId "2419146865" @default.
- W2419146865 workType "article" @default.